FDA Grants Breakthrough Therapy Designation to Magrolimab for MDS Treatment

被引：0

|

作者：

不详

机构：

来源：

ONCOLOGY-NEW YORK | 2020年 / 34卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：430 / 430

页数：1

相关论文

共 50 条

[1] FDA Grants Breakthrough Therapy Designation to Tiragolumab Atezolizumab Therapy for Metastatic NSCLC
Slater, Hannah
[J]. ONCOLOGY-NEW YORK, 2021, 35 (02): : 76 - 76
[2] Breakthrough-Therapy Designation - An FDA Perspective
Corrigan-Curay, Jacqueline
Mckee, Amy E.
Stein, Peter
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15): : 1457 - 1458
[3] Rapastinel receives FDA breakthrough therapy designation
不详
[J]. NURSE PRACTITIONER, 2016, 41 (04): : 56 - 56
[4] Reflections on 10 years of the FDA's breakthrough therapy designation
Mullard, Asher
[J]. NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (04) : 252 - 253
[5] Physician Perceptions of the FDA's Breakthrough Therapy Designation: An Update
Paquin, Ryan S.
Boudewyns, Vanessa
O'Donoghue, Amie C.
Aikin, Kathryn J.
[J]. ONCOLOGIST, 2022, 27 (01): : E85 - E88
[6] Reflections on 10 years of the FDA’s breakthrough therapy designation
Asher Mullard
[J]. Nature Reviews Drug Discovery, 2022, 21 : 252 - 253
[7] FDA Grants "Breakthrough Therapy" Status To Potential Autism Drug
Diament, Michelle
[J]. PALAESTRA, 2018, 32 (02) : 58 - 58
[8] Expediting Drug Development - The FDA's New "Breakthrough Therapy" Designation
Sherman, Rachel E.
Li, Jun
Shapley, Stephanie
Robb, Melissa
Woodcock, Janet
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20): : 1877 - 1880
[9] FDA breakthrough therapy designation for oncology products: The CBER experience.
Singh, Harpreet
Pazdur, Richard
Xu, Lei
Liu, Ke
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[10] Two Meningococcal B vaccines receive FDA, Breakthrough Therapy' designation
不详
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (06) : 1428 - 1429

← 1 2 3 4 5 →